Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Plasma cell 1Lymphoid 1

Conditions

Carcinoma, Non-Small-Cell Lung 14Multiple Myeloma 6Lung Neoplasms 6Lymphoma 5Lymphoma, Large-Cell, Anaplastic 3Hematologic Neoplasms 3Urinary Bladder Neoplasms 2Stomach Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Adenocarcinoma 2Uveal Melanoma 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Sarcoma, Clear Cell 1Sarcoma, Alveolar Soft Part 1Rhabdomyosarcoma, Alveolar 1Relapsed Pediatric Solid Tumor 1Rectal Neoplasms 1Rare Tumor 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neurofibromatosis 2 1

Interventions

cediranib 3perifosine 2pembrolizumab 2pazopanib 2atezolizumab 2Sunitinib 2Specimen Handling 2Loperamide 2selinexor 1sargramostim 1romidepsin 1cabozantinib 1brostallicin 1atropine sulfate-diphenoxylate hydrochloride drug combination 1Warfarin 1Vitamin B 6 1Trabectedin 1Thyroxine 1Temozolomide 1Radiotherapy, Intensity-Modulated 1Radiation Dose Hypofractionation 1Pyridoxine 1Promethazine 1Prochlorperazine 1Polymerase Chain Reaction 1Petrolatum 1Neoadjuvant Therapy 1Mass Spectrometry 1Lorazepam 1Immunoglobulin G 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Sarcoma, Alveolar Soft Part × Crizotinib × Clear all
NCT01524926 2023-12-11

CREATE

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Completed
582 enrolled
LymphoidPlasma cellSarcoma

Granuloma, Plasma Cell, Lymphoma, Large-Cell, Anaplastic, Sarcoma, Clear Cell, Rhabdomyosarcoma, Alveolar, Sarcoma, Alveolar Soft Part

Data powered by HemOnc (CC BY 4.0) Colophon âš¡